Drugs / Demineralized Bone Matrix
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT00851162 Comparator | Mar 2009 → Mar 2010 | bone neoplasm | Emory University | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT02070484 Comparator | Feb 2014 → Mar 2017 | lumbar disk degenerative disorder, spinal stenosis, spondylolisthesis, spondylolysis +1 | OhioHealth | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Demineralized bone matrix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00851162 ↗ |
| Known as | DBM | “Demineralized Bone Matrix (DBM) bone graft substitute” NCT02070484 ↗1“Demineralized bone matrix(DBM)” NCT00851162 ↗ |
| Modality | Other / unclassified | “Demineralized Bone Matrix (DBM) bone graft substitute” NCT02070484 ↗ |